TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19331473

Group type: EXPERIMENTAL
Intervention: New slowly backward-rotating shift schedule
Number of subjects: 118

Group type: COMPARATOR
Intervention: Initial fast forward-rotating shift schedule
Number of subjects: 118
Study: 17086911

Group type: EXPERIMENTAL
Intervention: Oromucosal cannabis-based medicine (CBM)
Number of subjects: 137
Study: 15589385

Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg/day
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg/day
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg QD
Number of subjects: 367

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study: 11759100

Group type: EXPERIMENTAL
Intervention: UltraSeal XT plus (filled sealant with drying agent)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Delton (unfilled sealant)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Air abrasion with acid etch
Number of subjects: 180

Group type: COMPARATOR
Intervention: Bur with acid etch
Number of subjects: 180
Study: 9263279

Group type: EXPERIMENTAL
Intervention: Oral glutamine supplementation after exhaustive exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral glutamine supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7522283

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg o.d.)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Captopril (25-50 mg b.i.d.)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both amlodipine and captopril
Number of subjects: 45
Study: 2891533

Group type: EXPERIMENTAL
Intervention: Flosequinan
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30761787

Group type: EXPERIMENTAL
Intervention: Transvesical prostatic adenomectomy (TPA)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection (TUR)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Prostate artery embolization (PAE)
Number of subjects: 39
Study: 27604979

Group type: COMPARATOR
Intervention: Placebo-controlled trials
Number of subjects: 0
Study: 25638616

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LN)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Open Nissen fundoplication (ON)
Number of subjects: 39
Study: 23302515

Group type: EXPERIMENTAL
Intervention: Fibular reposition taping (FRT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham tape intervention
Number of subjects: 12
Study: 20381287

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Fusidic acid
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 3
Study: 18958167

Group type: EXPERIMENTAL
Intervention: High levels of media reporting on diseases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent presentation of objective information about diseases
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low media frequency conditions
Number of subjects: 0
Study: 15723892

Group type: EXPERIMENTAL
Intervention: CBSM+ intervention (10-week group cognitive-behavioral stress management/expressive supportive therapy)
Number of subjects: 0
Study: 12830458

Group type: EXPERIMENTAL
Intervention: T + V (Trandolapril 2 mg + Verapamil 180 mg)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: T + A (Trandolapril 2 mg + Amlodipine 5 mg)
Number of subjects: 69

Group type: COMPARATOR
Intervention: T + A
Number of subjects: 69

Group type: COMPARATOR
Intervention: T + V
Number of subjects: 69
Study: 10390406

Group type: EXPERIMENTAL
Intervention: Ciclesonide 50 micrograms
Number of subjects: 29
Study: 8895271

Group type: EXPERIMENTAL
Intervention: Fentanyl 100 micrograms (Group I)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ketorolac 60 mg (Group II)
Number of subjects: 80
Study: 2000278

Group type: EXPERIMENTAL
Intervention: Early surfactant (given at birth)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Late surfactant (given at less than 6 hours of age)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control (dummy instillation of air given at birth)
Number of subjects: 182
Study: 6594786

Group type: EXPERIMENTAL
Intervention: Fluoride-containing sucking tablet (Fludent, 0.25 mg F) daily at bedtime for 3 years
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no fluoride tablet)
Number of subjects: 34
Study: 30538282

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 12
Study: 28183322

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1400
Study: 29071950

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (3 months duration)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Routine rehabilitation therapy (Control group)
Number of subjects: 130
Study: 22942273

Group type: EXPERIMENTAL
Intervention: Email-delivered intervention promoting fruit and vegetable consumption, consisting of an implementation intention 'planning task' and between 3 and 15 short email messages over a 15-day study period.
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Email-delivered intervention promoting fruit and vegetable consumption
Number of subjects: 110
Study: 22545609

Group type: EXPERIMENTAL
Intervention: Strong tests (high strength list studied 5 times)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weak tests (low strength list studied once)
Number of subjects: 0
Study: 19777216

Group type: EXPERIMENTAL
Intervention: Cocaine craving during periods of urine-verified cocaine use
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cocaine craving during the 5 hours prior to cocaine use
Number of subjects: 112

Group type: COMPARATOR
Intervention: Heroin craving and mood ratings
Number of subjects: 112
Study: 17900364

Group type: EXPERIMENTAL
Intervention: Whole milk (710 ml daily for one month)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Low fat (2%) milk (710 ml for one week)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Macronutrient substitute for milk (one week)
Number of subjects: 74
Study: 16078129

Group type: EXPERIMENTAL
Intervention: Stretching exercises performed three times a day starting the morning after surgery
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Stretching exercises
Number of subjects: 409

Group type: COMPARATOR
Intervention: Control group (no stretching exercises)
Number of subjects: 409
Study: 12090906

Group type: EXPERIMENTAL
Intervention: 12.5 mg (R)-carvedilol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 12.5 mg (S)-carvedilol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 25 mg (R,S)-carvedilol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 25 mg (R,S)-carvedilol (in patients with essential arterial hypertension)
Number of subjects: 23
Study: 10417506

Group type: EXPERIMENTAL
Intervention: (+)‐tramadol
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: racemate
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: (‐)‐tramadol
Number of subjects: 98
Study: 7675047

Group type: EXPERIMENTAL
Intervention: DTP toxoids
Number of subjects: 3448

Group type: COMPARATOR
Intervention: DT toxoids
Number of subjects: 3448

Group type: EXPERIMENTAL
Intervention: DTP toxoids after two doses
Number of subjects: 3448
Study: 2187551

Group type: EXPERIMENTAL
Intervention: Silver alloy coated Foley catheter
Number of subjects: 223

Group type: COMPARATOR
Intervention: Teflonised latex Foley catheter
Number of subjects: 223
Study: 7029988

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 2 g/die for 30 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 14
Study: 30856025

Group type: EXPERIMENTAL
Intervention: Fennel infusion plus dry cupping
Number of subjects: 61

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 61
Study: 27605588

Group type: EXPERIMENTAL
Intervention: PCV11
Number of subjects: 11729

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11729
Study: 27521997

Group type: EXPERIMENTAL
Intervention: RAR CLA (6g per day for 8 weeks)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (high oleic sunflower oil)
Number of subjects: 65
Study: 25172889

Group type: EXPERIMENTAL
Intervention: ET receptor blockade (bosentan)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 21737561

Group type: COMPARATOR
Intervention: Winter season
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate exacerbations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Severe exacerbations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Older age, lower body mass index, lower FEV(1) % pred, history of prior exacerbations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Female gender
Number of subjects: 0

Group type: COMPARATOR
Intervention: MRC dyspnoea score 3 versus 1 and 2 combined
Number of subjects: 0

Group type: COMPARATOR
Intervention: Seasonality effect
Number of subjects: 0
Study: 19543687

Group type: EXPERIMENTAL
Intervention: Iron-deficiency anemia and pagophagia with H. pylori infection before eradication
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Iron-deficiency anemia and pagophagia after H. pylori eradication
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iron-deficiency anemia without pagophagia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iron-deficiency anemia with pagophagia
Number of subjects: 100
Study: 17689600

Group type: EXPERIMENTAL
Intervention: Colorectal Web intervention
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard Web site (control)
Number of subjects: 174
Study: 15573192

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5mg/kg intravenous
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 60
Study: 11286152

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 598
Study: 9752650

Group type: EXPERIMENTAL
Intervention: Surgical repair of the supraspinatus tendon
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control case (intact musculotendinous unit)
Number of subjects: 4
Study: 8118970

Group type: EXPERIMENTAL
Intervention: Cemented total hip arthroplasty
Number of subjects: 250

Group type: COMPARATOR
Intervention: Cementless total hip arthroplasty
Number of subjects: 250
Study: 2898859

Group type: EXPERIMENTAL
Intervention: betaxolol 0.5% drops
Number of subjects: 41

Group type: COMPARATOR
Intervention: timolol 0.5% drops
Number of subjects: 41
Study: 16321158

Group type: EXPERIMENTAL
Intervention: Etoricoxib 30 mg
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg
Number of subjects: 617

Group type: COMPARATOR
Intervention: Diclofenac 150 mg
Number of subjects: 617
Study: 31904629

Group type: EXPERIMENTAL
Intervention: Chronic Liver Disease Nurse (CLDN) role
Number of subjects: 0
Study: 31062731

Group type: EXPERIMENTAL
Intervention: Vitamin D serum level
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: VDR Fok1 polymorphism distribution
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group VDR Fok1 polymorphism distribution
Number of subjects: 47
Study: 27751603

Group type: EXPERIMENTAL
Intervention: EG1 (14.5 °C from 1 to 50 dph, then 20 °C until 176 dph)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: EG2 (14.5 °C from 1 to 37 dph, then 20 °C until 226 dph)
Number of subjects: 120

Group type: COMPARATOR
Intervention: CG1 (15.0 °C for 10 dph, then 19.0 °C until 176 dph)
Number of subjects: 120

Group type: COMPARATOR
Intervention: CG2 (15.0 °C for 10 dph, then 19.0 °C until 226 dph)
Number of subjects: 120
Study: 26550815

Group type: EXPERIMENTAL
Intervention: Lumbo-pelvic core stabilization training (LPST)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo treatment with passive cycling (PC)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Controlled intervention with rest (CI)
Number of subjects: 25
Study: 24376842

Group type: EXPERIMENTAL
Intervention: Planned caesarean section at 38 weeks and three days
Number of subjects: 1274

Group type: COMPARATOR
Intervention: Planned caesarean section at 39 weeks and three days
Number of subjects: 1274
Study: 21705403

Group type: EXPERIMENTAL
Intervention: R2 (20 W to 90% LT bouts separated by 30 s at 20 W)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: S2 (two step increments in work rate)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: S1 (two step increments in work rate)
Number of subjects: 15

Group type: COMPARATOR
Intervention: F control bouts (two 20 W to 90% LT bouts separated by 12 min at 20 W)
Number of subjects: 15
Study: 18212314

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (diuretic)
Number of subjects: 38462

Group type: COMPARATOR
Intervention: Amlodipine (calcium antagonist)
Number of subjects: 38462

Group type: COMPARATOR
Intervention: Lisinopril (ACE inhibitor)
Number of subjects: 38462

Group type: COMPARATOR
Intervention: Doxazosin (alpha-blocker)
Number of subjects: 38462
Study: 17068625

Group type: EXPERIMENTAL
Intervention: General anesthesia followed with postoperative intravenous analgesia (n=53)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Combined general-epidural anesthesia followed with postoperative epidural analgesia (n=50)
Number of subjects: 103
Study: 12941494

Group type: EXPERIMENTAL
Intervention: Educational intervention on generic drugs (verbal information and handout materials)
Number of subjects: 4620

Group type: EXPERIMENTAL
Intervention: Generic prescribing in intervention practices
Number of subjects: 4620

Group type: COMPARATOR
Intervention: Generic prescribing in control practices
Number of subjects: 4620
Study: 10642232

Group type: EXPERIMENTAL
Intervention: Clinical variables related to left ventricular systolic dysfunction
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Electrocardiogram with Q waves, left bundle branch block, or ST‐T segment changes
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Resting supine heart rate greater than simultaneous diastolic blood pressure
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Plasma N‐terminal atrial natriuretic peptide >0.8 nmol/l
Number of subjects: 126

Group type: COMPARATOR
Intervention: Normal electrocardiogram
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Two or three positive responses to clinical questions
Number of subjects: 126
Study: 9342765

Group type: EXPERIMENTAL
Intervention: 1800 mg LI 160/die
Number of subjects: 0

Group type: COMPARATOR
Intervention: 150 mg imipramine/die
Number of subjects: 0
Study: 7506580

Group type: COMPARATOR
Intervention: GM-CSF
Number of subjects: 115

Group type: COMPARATOR
Intervention: IL-1
Number of subjects: 115

Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control
Number of subjects: 115
Study: 3097159

Group type: EXPERIMENTAL
Intervention: Terfenadine (sufficient dose to cause maximum H1 receptor blockade)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Histamine (acting on the H1 receptor)
Number of subjects: 0
Study: 31925317

Group type: EXPERIMENTAL
Intervention: Imatinib (IM) and hydroxychloroquine (HCQ)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Imatinib (IM) alone
Number of subjects: 62
Study: 28836154

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (MH, n = 40, nasopharyngeal temperature 25 °C, rectal temperature 28 °C)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (MH)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Deep hypothermia (DH, n = 42, nasopharyngeal temperature 20 °C, rectal temperature 25 °C)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Deep hypothermia (DH)
Number of subjects: 82
Study: 26036675

Group type: EXPERIMENTAL
Intervention: Physiotherapy (eight sessions of elbow manipulation and exercise)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection plus physiotherapy
Number of subjects: 165

Group type: COMPARATOR
Intervention: Saline injection (placebo)
Number of subjects: 165
Study: 25643201

Group type: EXPERIMENTAL
Intervention: Reflective thinking (higher levels of reflection) in individuals low in both mindfulness and memory specificity.
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Reflective thinking (higher levels of reflection) in all other groups (not low in mindfulness and memory specificity).
Number of subjects: 274
Study: 23953523

Group type: EXPERIMENTAL
Intervention: Reduced-dose tacrolimus plus sirolimus (rTAC)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard-dose tacrolimus and sirolimus (sTAC)
Number of subjects: 128
Study: 21131677

Group type: EXPERIMENTAL
Intervention: Multisensory environments (MSEs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control activity
Number of subjects: 30
Study: 17852727

Group type: EXPERIMENTAL
Intervention: Misinformation narrative
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control narrative
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Sequential retrieval order
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Random retrieval order
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Delay (2 weeks)
Number of subjects: 232
Study: 15871445

Group type: EXPERIMENTAL
Intervention: Celecoxib (Celebrex 200 mg, Pfizer, Turkey)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 12635913

Group type: EXPERIMENTAL
Intervention: Mortality salience
Number of subjects: 0
Study: 11789239

Group type: EXPERIMENTAL
Intervention: Rhinitis Spray (RS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 80
Study: 9376336

Group type: COMPARATOR
Intervention: Haloperidol (15 +/- 5 mg/day)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 +/- 2.5 mg/day)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Olanzapine (10 +/- 2.5 mg/day)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Olanzapine (15 +/- 2.5 mg/day)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Olanzapine (all doses)
Number of subjects: 202
Study: 8258676

Group type: EXPERIMENTAL
Intervention: Lisinopril (10-40 mg/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nifedipine (30-90 mg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 3937666

Group type: EXPERIMENTAL
Intervention: Sustak-forte preparation (nitroglycerin with prolonged action)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Nitrates
Number of subjects: 64

Group type: COMPARATOR
Intervention: No nitrates (control group)
Number of subjects: 64
Study: 30675708

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg for 6 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 29246467

Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Number of subjects: 197

Group type: COMPARATOR
Intervention: Delayed cord clamping (DCC)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 197
Study: 27407100

Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Bevacizumab combination arm
Number of subjects: 218

Group type: COMPARATOR
Intervention: CA-125
Number of subjects: 218

Group type: COMPARATOR
Intervention: Concordant PD by RECIST and CA-125
Number of subjects: 218
Study: 25247944

Group type: EXPERIMENTAL
Intervention: Metal Artifact Reduction (MAR) software
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard reconstruction
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: MAR reconstruction
Number of subjects: 53
Study: 22537387

Group type: COMPARATOR
Intervention: Placebo administration in pre-treated patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo administration in drug-naïve patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administration in pre-treated patients (SP792 study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rotigotine group responses
Number of subjects: 0
Study: 20495588

Group type: EXPERIMENTAL
Intervention: 80 mg intravenous ketamine infusion diluted in 500 cc normal saline over a 5 hour period daily for one week and 300 mg of gabapentin 3 times daily.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo infusion and 300 mg of gabapentin 3 times daily.
Number of subjects: 40
Study: 18833861

Group type: EXPERIMENTAL
Intervention: NaF 5000 ppm (Prevident, Colgate)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Artificial saliva
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: MI paste (Recaldent, GC America Inc)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: NaF 1100 ppm (Crest, Procter & Gamble)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: NaF 1100 ppm plus MI paste
Number of subjects: 21
Study: 11696146

Group type: EXPERIMENTAL
Intervention: Bupivacaine + clonidine 1 microg x kg(‐1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bupivacaine + clonidine 2 microg x kg(‐1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 75
Study: 9209186

Group type: EXPERIMENTAL
Intervention: Substitute (sugar and coloring)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Coffee (continuation of coffee)
Number of subjects: 139
Study: 8431046

Group type: EXPERIMENTAL
Intervention: Intercostal bupivacaine (0.5% bupivacaine, 360 mg/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Intercostal saline solution (control group)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Fixed-schedule intramuscular buprenorphine
Number of subjects: 86
Study: 2956864

Group type: EXPERIMENTAL
Intervention: Enoximone 1 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enoximone 2 mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29746227

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg twice daily for 3 weeks, then 20 mg once daily for a total of 6 months)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Dalteparin (200 IU/kg daily during month 1, then 150 IU/kg daily for months 2-6)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 406

Group type: COMPARATOR
Intervention: Dalteparin
Number of subjects: 406
Study: 28497265

Group type: EXPERIMENTAL
Intervention: Proteomic analysis of pleomorphic adenoma (PA)
Number of subjects: 13